The counter has had a total traded volume of 28843 shares so far with a value of Rs 2.8 crore on the NSE. It traded at a price-to-earnings multiple of 10.72 and a price-to-book ratio of 1.44.
A higher P/E ratio shows investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations.
The price-to-book value indicates the inherent value of a company and reflects the price investors are willing to pay even for no growth in the business.
The scrip gained 25.68 per cent during the past one year, while the 30-share index advanced 47.79 per cent during the same period.
Aurobindo Pharma Ltd. belongs to the Pharma – Indian industry.
Promotor/FII Holding
Promoters held 48.86 per cent stake in the company as of 31-Mar-2021, while foreign investors and domestic institutional investors ownership stood at 24.37 per cent and 8.84 per cent, respectively.
Key Financials
The firm reported consolidated net sales of Rs 6079.6 crore for the quarter ended 31-Mar-2021, down 6.44 per cent from the previous quarter’s Rs 6498.31 crore and down 1.8 per cent from the year-ago quarter’s Rs 6191.02 crore.
Profit for the latest quarter stood at Rs 801.58 crore, down 5.68 per cent from the same quarter a year ago.
